Oncology

Latest News

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com

Novel, Noninvasive Skin Cancer Detection Method Shows Promise

By Jared Kaltwasser

May 18th 2025

The tool could make it easier for clinicians to rule out melanoma without the need for excision.

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health

New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

By Pearl Steinzor

May 14th 2025

At 3 months, hospitalizations among patients enrolled in RSM were 19% lower vs historical controls. | Image Credit: Nuttapong punna - stock.adobe.com

Remote Symptom Monitoring Linked to Reduced Hospitalization Risk for Patients With Cancer

By Rose McNulty

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

June 18th 2014

Fast Track Status for the Oncolytic Virus Treatment Being Developed by DNAtrix

The oncolytic adenovirus vaccine, DNX-2401, being developed by DNAtrix to treat recurrent glioblastoma, has received a fast-track status by the FDA.

June 18th 2014

3D Mammograms More Powerful than 2D

In community-based radiology practice, mammography screening with 3D digital breast tomosynthesis (DBT) yielded lower recall rates, an increased overall cancer detection rate, and an increased detection rate for invasive cancer compared with 2D digital mammography (DM).

June 17th 2014

Personalized Mouse TumorGrafts to Evaluate Treatment Benefits

Icahn School of Medicine at Mount Sinai and Champions Oncology have initiated a study evaluating TumorGrafts' ability to predict treatment benefit in patients with triple-negative breast cancer. A side-by-side genomic analysis of patients' tumor and TumorGraft mouse avatars, before and after treatment, will also be conducted.

June 17th 2014

Low-dose Dexamethasone with Pomalidomide Significantly Improves OS in MM

Low-dose dexamethasone with pomalidomide improved overall survival to 12.7 months, compared to 5.7 months with high-dose dexamethasone.

June 16th 2014

Lung-MAP Study Kicked-off at Multiple Hospitals in the United States

A bold new way to test cancer drugs started Monday in hundreds of hospitals around the United States.

June 16th 2014

Proteomics to Confirm Treatment Benefit in NSCLC

A proteomic test can predict outcome with chemotherapy versus erlotinib in NSCLC patients.

June 16th 2014

OncoMed Halts Enrollment and Phase 1 Dosing Studies for Vantictumab and Fzd8-Fc

June 13th 2014

NICE Proposes Ipilimumab as First-Line for Advanced Melanoma

June 13th 2014

Lymphoseek Receives FDA Approval For Diagnosis of HNSCC

The FDA has approved the diagnostic agent technetium 99m tilmanocept for the detection of the spread of head and neck cancers.

June 13th 2014

Sophisticated Chest Scans in Children: Increased Risk of Heart Disease

Cutting edge technology used to image young children with heart disease increases their risk of cancer.

June 12th 2014

Ventana and MedImmune to Develop a PD-L1 Assay To Aid Patient Enrollment in Immunotherapy Trials

Ventana Medical Systems, Inc. and MedImmune today announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only patients who express PD-L1 as determined by the VENTANA assay.

June 12th 2014

Low Cholesterol Reduces Survival in Kidney Cancer

New research suggests that a reduction in blood cholesterol might actually prove harmful in kidney cancer patients.

June 11th 2014

CYRAMZA Meets Secondary Endpoints in Phase 3 REACH Trial for HCC

CYRAMZAâ„¢ (ramucirumab)did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant, in patients with hepatocellular carcinoma, but meaningful improvements in key secondary endpoints of progression-free survival, overall response rate and time to progression were observed.

June 11th 2014

The Promise of Merck's Pembrolizumab in PD-L1-expressing NSCLC

Pembrolizumab was safe and effective in patients with locally advanced or metastatic non—small cell lung cancer that strongly expressed PD-L1, according to study results presented at the ASCO Annual Meeting.

June 11th 2014

Improved Detection of Metastasized Prostate Cancer with a New Tracer

A study conducted at the Johns Hopkins University demonstrates improved detection of prostate cancer metastasis following the injection of 18F-DCFBC, which binds PSMA.

June 10th 2014

Rosetta Genomics and Moffitt to Develop microRNA-Based Diagnostic

The agreement will help develop Rosetta's thyroid neoplasia assay.

June 10th 2014

Herceptin Can Lead to Heart Problems

Nearly 10% of women treated with herceptin were found to be susceptible to heart risks, which reversed once treatment was halted.

June 10th 2014

Study Identifies Substantial Variability in the Cost of Prostate Cancer Surgery

Patients who want to compare prices for prostate-cancer surgery may find it rough going: a study has found a 13-fold difference in prices quoted by 100 hospitals across the United States. Moreover, most provided little more than broad estimates, and only three gave a hard copy of the charges.

June 9th 2014

Clinical Pathways, ACOs, COAs: Introducing 'Value' in Cancer Care

The continued advances in cancer treatment are improving patient survival, but the healthcare industry is bursting at its seams.

June 9th 2014

Taiho's RECOURSE Trial Meets Primary Endpoint for mCRC in Phase 3

Taiho Pharmaceutical Co., parent company of Taiho Oncology, announced recently that its combination drug for refractory metastatic colorectal cancer met its primary endpoint in a phase 3 global RECOURSE trial.

June 9th 2014

Multiple Studies Show Medicaid Patients Receive Worse Cancer Care

Katie Sullivan, MA

New studies suggest that privately insured patients may receive better cancer care than Medicaid beneficiaries. Although a variety of factors impact patient access to cancer treatment, low-income patients were found to have greater difficulty with navigating health systems.

June 6th 2014

Weight Loss Surgery Can Reduce Cancer Risk

Weight loss surgery might have more value than simply helping morbidly obese people to shed unhealthy extra pounds. It reduces their risk of cancer to rates almost similar to those of people of normal weight.

June 6th 2014

Study Identifies Growing Pains of Navigation and Survivorship Programs at Cancer Institutes

A study conducted at the GW Cancer Institute identified issues faced by cancer care institutes in adopting patient-centered care programs.

June 6th 2014

Nanotubes to Destroy Pancreatic Tumors from Within

Pristine nanotubes produced through a new process can be modified to carry drugs to tumors through gaps in blood-vessel walls that larger particles cannot fit through. The nanotubes may then target and infiltrate the cancerous cells' nuclei, where the drugs can be released through sonication.

June 5th 2014

Cancer Patients on Medicaid Fair Poorly

June 5th 2014

Anti-MET Antibody Fails to Impress in Phase 3 NSCLC Trial

Onartuzumab (MetMab)did not improve PFS when combined with erlotinib (Tarceva) in the METLung trial.

June 5th 2014

ASCO to Help Cancer Docs Evaluate Treatment Value

The American Society of Clinical Oncology's algorithm to help oncologists evaluate the clinical benefits, side effects and costs of a cancer drug or therapy will be fine-tuned over the summer and should be available for public comment by the fall, said Dr. Lowell Schnipper, chair of the society's Value in Cancer Care Task Force.

June 5th 2014

Carl June Receives 2014 Taubman Prize for his Pioneering Work in Adoptive Cell Transfer

A physician-scientist who developed a personalized immunotherapy for leukemia using patients' own T cells is the recipient of the 2014 Taubman Prize for Excellence in Translational Medical Science, awarded by the A. Alfred Taubman Medical Research Institute at the University of Michigan Medical School.

June 4th 2014

Ipilimumab for Early-Stage Melanoma?

Despite promising results, experts believe it's too early to use ipilimumab for early-stage melanoma, high toxicity being one of the limiting factors.

June 4th 2014

Phase 3 Studies of Lilly's CYRAMZA (ramucirumab): Significant Improvement in NSCLC Survival

Lilly's CYRAMZA (ramucirumab) significantly improved overall survival in phase 3 non-small cell lung cancer study. Results from the REVEL trial were published in The Lancet and also presented at ASCO 2014.

...

158 159 160 161 162 163 164 165 166

...

185 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions